Preview

Rational Pharmacotherapy in Cardiology

Advanced search

How to Choose the Optimal Single-Pill Combination of the First-Line Antihypertensive Drugs? The Benefits of Amlodipine and Telmisartan Combination

https://doi.org/10.20996/1819-6446-2020-07-01

Full Text:

Abstract

In patients with arterial hypertension (AH), an extremely important measure of the effectiveness of antihypertensive drugs (AHD) is not only a direct decrease in blood pressure (BP), but also its stable control throughout the 24 hours, preventing excessive morning surge and increased BP variability, which in turn are recognized cardiovascular risk factors. Currently, in the vast majority of hypertensive patients, the main antihypertensive therapy approach is using single-pill combinations (SPC) of AHD. Among the first-line combinations for a wide range of patients with AH and no special clinical conditions is amlodipine/telmisartan SPC. Distinctive features of these drugs, on the one hand, are unique pharmacological properties, consisting in an ultra-long antihypertensive effects, superior to other AHD in their classes; and on the other hand, there is an large body of evidence from numerous clinical trials confirming their high antihypertensive and target-organ protective potential as well as excellent capabilities in cardiovascular risk reduction. To assess the AHD effectiveness extent, several parameters have been proposed, of which the most rational and useful is the smoothness index, calculated using the ambulatory blood pressure monitoring data. Smoothness index describes both the degree of BP reduction and its distribution during the monitoring period. This index inversely associates with the changes in BP variability, and has predictive value in relation to the hypertension-mediated organ damage regression during different antihypertensive regimens. Amlodipine/telmisartan SPC has also been studied in many trials, including comparative ones with other AHD. In these works its direct powerful antihypertensive effect and a pronounced beneficial impact on the smoothness index have been proved, demonstrating stable BP control throughout the 24 hours (especially in the most dangerous morning hours), and also a decrease in BP variability. Therefore, amlodipine/telmisartan SPC can effectively reduce cardiovascular risk and improve prognosis in patients with AH.

About the Authors

O. D. Ostroumova
Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Olga D. Ostroumova – MD, PhD, Professor, Head of Chair of Therapy and Polymorbid Pathology, Russian Medical Academy of Continuous Professional Education; Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Sechenov University

Barrikadnaya ul. 2/1, Moscow, 125993, 

Trubetskaya ul. 8-2, Moscow, 119991



A. I. Kochetkov
Medical Academy of Continuous Professional Education
Russian Federation

Alexey I. Kochetkov – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



V. N. Butorov
Medical Academy of Continuous Professional Education
Russian Federation

Vasilii N. Butorov – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



I. F. Krotkova
Medical Academy of Continuous Professional Education
Russian Federation

Irina F. Krotkova – MD, PhD, Associate Professor, Chair of Therapy and Polymorbid Pathology

Barrikadnaya ul. 2/1, Moscow, 125993



References

1. Clinical guidelines of the Russian Ministry of Health "Arterial hypertension in adults" [cited by Jun 27, 2020]. Available from: http://cr.rosminzdrav.ru/#!/recomend/687 (In Russ.)

2. Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.

3. Balanova Y.A., Shalnova S.A., Imaeva A.E., et al. on behalf of ESSE-RF-2 researchers. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSE-RF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-66 (In Russ.) DOI:10.20996/1819-6446-2019-15-4-450-466.

4. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002;360(9349):1903-13. DOI:10.1016/S0140-6736(02)11911-8.

5. Erina A.M., Rotar O.P., Solntsev V.N., et al. Epidemiology of Arterial Hypertension in Russian Federation - Importance of Choice of Criteria of Diagnosis. Kardiologiia. 2019;59(6):5-11 (In Russ.) DOI:10.18087/cardio.2019.6.2595.

6. Peixoto A.J., White W.B. Circadian blood pressure: clinical implications based on the pathophysiology of its variability. Kidney Int. 2007;71(9):855-60. DOI:10.1038/sj.ki.5002130.

7. Willich S.N., Levy D., Rocco M.B., et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol. 1987;60:801-6. DOI:10.1016/0002-9149(87)91027-7.

8. Elliott W.J. Circadian variation in the timing of stroke onset. А meta-analysis. Stroke. 1998;29:992-6. DOI:10.1161/01.STR.29.5.992.

9. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2010;56(5):765-73. DOI:10.1161/HYPERTENSIONAHA.110.157149.

10. Höcht C. Blood Pressure Variability: Prognostic Value and Therapeutic Implications. ISRN Hypertension. 2013; 2013:article ID 398485. DOI:10.5402/2013/398485.

11. Parati G., Pomidossi G., Albini F., et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. Journal of Hypertension. 1987;5(1):93-8. DOI: 10.1097/00004872-198702000-00013.

12. Mancia G., Parati G., Hennig M., et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). Journal of Hypertension. 2001;19(11):1981-9. DOI:10.1097/00004872-200111000-00008.

13. Sega R., Corrao G., Bombelli M., et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study. Hypertension 2002;39(2):710-14. DOI:10.1161/hy0202.104376.

14. McMullan C.J., Bakris G.L., Phillips R.A., Forman J.P. Association of BP variability with mortality among African Americans with CKD. Clinical Journal of the American Society of Nephrology 2013;8(5):731- 8. DOI: 10.2215/CJN.10131012.

15. Kawai T., Ohishi M., Kamide K. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertension Research. 2013;36(3):232-9. DOI: 10.1038/hr.2012.162.

16. Schillaci G., Bilo G., Pucci G., et al. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. Hypertension. 2012;60(2):369-77. DOI:10.1161/HYPERTENSIONAHA.112.197491.

17. Schutte A.E., Schutte R., Huisman H.W., et al. Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: The SABPA Study. Hypertension Research. 2011;34(10):1127-34. DOI:10.1038/hr.2011.104.

18. Sakakura K., Ishikawa J., Okuno M., et al. Exaggerated ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly. American Journal of Hypertension. 2007;20(7):720-7. DOI:10.1016/j.amjhyper.2007.02.001.

19. Parati G., Ulian L., Santucciu C., et al. Blood pressure variability, cardiovascular risk and antihypertensive treatment. J Hypertens Suppl. 1995;13(4):S27-S34. DOI:10.1097/00004872-199512002-00005.

20. Frattola A., Parati G., Cuspidi C. et al. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11(10):1133-7. DOI:10.1097/00004872-199310000-00019.

21. Dahlöf B., Sever P.S., Poulter N.R., et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.

22. Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res. 2009;37(6):1662-79. DOI:10.1177/147323000903700602.

23. Kakuta H., Sudoh K., Sasamata M., Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25(1):41-6.

24. Abraham H.M., White C.M., White W.B. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015;38(1):33-54. DOI:10.1007/s40264-014-0239-7.

25. Stangier J., Su C.A., van Heiningen P.N., et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol. 2001;38(5):672-85. DOI:10.1097/00005344-200111000-00004.

26. Radchenko A.D. Some aspects of dihydropyridine calcium antagonists in the treatment of hypertension. Part 1. Arterialnaya Gipertenziia. 2013;5(31):81-98 (In Russ.)

27. Neldam S., Edwards C., Jones R.; TEAMSTA-10 Investigators. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin. 2011;27(11):2145-53. DOI:10.1185/03007995.2011.624089.

28. Sharma A., Bagchi A., Kinagi S.B., et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther. 2007;29(12):2667-76. DOI:10.1016/j.clinthera.2007.12.017.

29. Goyal J., Khan Z.Y., Upadhyaya P., et al. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res. 2014;8(6):HC08-11. DOI:10.7860/JCDR/2014/9352.4500.

30. Neutel J.M., Mancia G., Black H.R., et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich). 2012;14(4):206-15. DOI:10.1111/j.1751-7176.2012.00595.x.

31. Littlejohn T.W. 3rd, Majul C.R., Olvera R., et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(4):207-13. DOI:10.1111/j.1751-7176.2009.00098.x.

32. Neldam S., Dahlöf B., Oigman W., Schumacher H. Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals. Int J Clin Pract. 2013;67(9):843-52. DOI:10.1111/ijcp.12180.

33. Fogari R., Zoppi A., Maffioli P., et al. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opin Pharmacother. 2011;12(16):2441-8. DOI:10.1517/14656566.2011.623698.

34. Rizzoni D., Muiesan M.L., Salvetti M., et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens. 2001;19(4):703-11. DOI:10.1097/00004872-200104000-00007.

35. Parati G., Omboni S., Rizzoni D., et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16(11):1685-91. DOI:10.1097/00004872-199816110-00016.

36. Parati G., Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Hypertens Res. 2014;37(3):187-93. DOI:10.1038/hr.2013.145.

37. Parati G., Dolan E., Ley L., Schumacher H. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens. 2014;32(6):1326-33. DOI:10.1097/HJH.0000000000000169.

38. Campo C., Saavedra J., Segura J., et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005;96(5):365-71.

39. Parati G. Telmisartan Plus Amlodipine Combination Significantly Improves 24-h Blood Pressure Smoothness Index Compared with Monotherapies. The 4th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus. Paris, 1 December - 4 December 2011.

40. Parati G., Schumacher H., Bilo G., Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010;28(11):2177-83. DOI:10.1097/HJH.0b013e32833e1150.

41. Williams B., Gosse P., Lowe L., Harper R.; PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24(1):193-200. DOI:10.1097/01.hjh.0000194364.11516.ab.

42. Lacourcière Y., Neutel J.M., Davidai G., Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19(1):104-12. DOI:10.1016/j.amjhyper.2005.10.001.

43. Lacourcière Y., Krzesinski J.M., White W.B., et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9(4):203-10. DOI:10.1097/00126097-200408000-00005.

44. Smith D.H., Cramer M.J., Neutel J.M., et al Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit. 2003;8(3):111-7. DOI:10.1097/00126097-200306000-00004

45. Ding P.Y., Chu K.M., Chiang H.T., Shu K.H. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl. 2004;(145):16-22. DOI:10.1111/j.1742-1241.2004.00405.x.

46. Derosa G., Ragonesi P.D., Mugellini A., et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27(7):457- 64. DOI:10.1291/hypres.27.457.

47. Fogari R., Mugellini A., Zoppi A., et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177-85. DOI: 10.1038/sj.jhh.1001964.

48. Williams B., Gosse P., Lowe L., Harper R.; PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24(1):193-200. DOI:10.1097/01.hjh.0000194364.11516.ab.

49. Lacourcière Y., Neutel J.M., Davidai G., Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens. 2006;19(1):104-112. DOI:10.1016/j.amjhyper.2005.10.001.

50. Williams B., Lacourcière Y., Schumacher H., et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23(9):610-9. DOI:10.1038/jhh.2009.4.

51. Smilde J.S. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Current Therapeutic Research. 1997;58(3):141- 53. DOI: 10.1016/S0011-393X(97)80009-4.

52. Ongtengco I., Morales D., Sanderson J., et al. Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two 'missed doses': a randomised, double-blind comparative trial in Asian patients. J Hum Hypertens. 2002;16(11):805-13. DOI:10.1038/sj.jhh.1001485


For citation:


Ostroumova O.D., Kochetkov A.I., Butorov V.N., Krotkova I.F. How to Choose the Optimal Single-Pill Combination of the First-Line Antihypertensive Drugs? The Benefits of Amlodipine and Telmisartan Combination. Rational Pharmacotherapy in Cardiology. 2020;16(4):614-622. (In Russ.) https://doi.org/10.20996/1819-6446-2020-07-01

Views: 46


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)